Business Wire

Sultan bin Ahmed Lays Foundation Stone for Al Reeh Al Mursala Village in Sri Lanka

25.9.2025 19:59:00 CEST | Business Wire | Press Release

Share

His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, laid the foundation stone for Al Reeh Al Mursala Village in the Puttalam region of the Republic of Sri Lanka. The project, launched as part of a wider humanitarian initiative, includes the construction of 50 homes, a mosque that accommodates 200 worshippers, a healthcare centre, and various essential service facilities designed to support the wellbeing of the local community.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250925201754/en/

Sultan bin Ahmed lays foundation for Al Reeh Al Mursala Village (Photo: AETOSWire)

In addition to launching the village project, His Highness also inaugurated a fully equipped mobile medical clinic, aimed at delivering emergency medical services and conducting routine health screenings. The mobile unit will serve residents of Al Reeh Al Mursala and neighbouring villages, significantly improving access to healthcare in remote and underserved areas.

This initiative is supported by the Al Reeh Al Mursala programme, developed and broadcast by the Sharjah Broadcasting Authority (SBA) in partnership with Sharjah Charity International (SCI). His Highness affirmed that the charitable projects implemented in Sri Lanka are a result of this strong collaboration, and are a continuation of Sharjah’s commitment to spreading humanitarian values and supporting those in need globally.

His Highness highlighted that these efforts reflect the directives and vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, who continuously encourages acts of compassion and extending support to vulnerable communities. He noted that humanitarian action is a foundational part of Sharjah’s international engagement, not only addressing urgent needs but also promoting dignity and long-term wellbeing.

During his visit, His Highness expressed his deep appreciation to all individuals and organisations contributing to this humanitarian work. He noted that the collective efforts of donors, partners, and the community present a bright and honourable image of the UAE and Sharjah on the global stage—strengthening the values of generosity and solidarity that the nation stands for.

Mohammed Hassan Khalaf, Director General of the Sharjah Broadcasting Authority, described the Sri Lanka projects as a new milestone for the Al Reeh Al Mursala programme. Broadcast annually during Ramadan, the initiative supports the construction of vital infrastructure such as villages, schools, and hospitals. He praised the ongoing partnership with Sharjah Charity International as a strong model of effective humanitarian cooperation. Khalaf also highlighted the importance of field visits in ensuring aid reaches those most in need and in guiding efforts based on real, on-the-ground conditions.

The Al Reeh Al Mursala Village will include 50 solar-powered homes, a mosque, a health centre, a children’s park, a sewing centre, and a clean water well. A mobile clinic will provide flexible, accessible healthcare. His Highness also reviewed aid distribution, including food, sewing machines, bicycles, and wheelchairs to support family income and self-reliance. Since its launch 14 years ago, Al Reeh Al Mursala has raised approximately AED 67 million, supporting humanitarian projects in over 110 countries. Funded initiatives include the Little Hearts Campaign, eye surgeries, orphan sponsorships, construction of mosques and schools, medical centres, water wells, and a wide range of income-generating programmes.

His Highness was accompanied by Sheikh Saqr bin Mohammed Al Qasimi, Chairman of the Board of Directors of Sharjah Charity International; Khalid Nasser Al Ameri, UAE Ambassador to Sri Lanka; Mohammed Hassan Khalaf, Director General of SBA; Tariq Saeed Allay, Director General of the Sharjah Government Media Bureau; Hassan Yaqoub Al Mansouri, Secretary-General of the Sharjah Media Council; and several senior officials and media executives from Sharjah.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250925201754/en/

Contacts

Hussain Al Mulla
Hussain.AlMulla@SGMB.ae

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye